The Effect of Mydriatic Solutions on Cognitive Function

Dersu, Inci; Spencer, Horace J.; Grigorian, Paula A.; Evans, Megan S.; Harper, Richard A.

doi:10.3109/08820538.2013.810289

Cited by 4 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are limited studies on the assessment of cognitive effects of mydriatic eye solutions, which mostly include ACs. A study based on Montreal's cognitive assessment could not detect a significant difference in cognitive function with and without using the mydriatic solutions 2 . None of our included studies assess the cognitive safety of AC eye drop solutions.…”

Section: Discussionmentioning

confidence: 94%

“…Atropine, scopolamine, glycopyrrolate, tiotropium, and benztropine are examples of antimuscarinic drugs and mecamylamine is one of the antinicotinics. The uses of ACs range from disorders of the central nervous system (CNS) such as Parkinson's disease (PD) and motion sickness to ophthalmologic disorders, chronic obstructive pulmonary disease (COPD), cardiovascular disorders, gastrointestinal disorders like peptic ulcer disease, and finally lower urinary tract symptoms (LUTS) [1][2][3] . Patients with psychiatric problems are also the other users of these medications 4 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cognitive effects of individual anticholinergic drugs: a systematic review and meta-analysis

Naseri

Sadigh-Eteghad

Seyedi‐Sahebari

et al. 2023

Dement. neuropsychol.

View full text Add to dashboard Cite

ABSTRACT. Anticholinergics (ACs) are among the most prescribed drugs. Investigating the impaired cognitive domains due to individual ACs usage is associated with controversial findings. Objective: The objective of this study was to investigate the effects of individual ACs on different aspects of cognitive function based on clinical trial studies. Methods: This systematic review was conducted following the PRISMA statement. A systematic search was performed in Embase, PubMed, Cochrane Library, Scopus, and Web of Science databases. Risk of bias (RoB) was assessed by the Joanna Briggs Institute checklists and the meta-analysis was performed using the CMA software. Results: Out of 3,026 results of searching, 138 studies were included. A total of 38 studies that assess the cognitive impacts of scopolamine were included in the meta-analysis. Included studies reported cognitive effects of scopolamine, mecamylamine, atropine, biperiden, oxybutynin, trihexyphenidyl, benzhexol, and dicyclomine; however, glycopyrrolate, trospium, tolterodine, darifenacin, fesoterodine, tiotropium, and ipratropium were not associated with cognitive decline. Based on the meta-analyses, scopolamine was associated with reduced recognition (SDM -1.84; 95%CI -2.48 to -1.21; p<0.01), immediate recall (SDM -1.82; 95%CI -2.35 to -1.30; p<0.01), matching to sample (SDM -1.76; 95%CI -2.57 to -0.96; p<0.01), delayed recall (SDM -1.54; 95%CI -1.97 to -1.10; p<0.01), complex memory tasks (SDM -1.31; 95%CI -1.78 to -0.84; p<0.01), free recall (SDM -1.18; 95%CI -1.63 to -0.73; p<0.01), cognitive function (SDM -0.95; 95%CI -1.46 to -0.44; p<0.01), attention (SDM -0.85; 95%CI -1.38 to -0.33; p<0.01), and digit span (SDM -0.65; 95%CI -1.21 to -0.10; p=0.02). There was a high RoB in our included study, especially in terms of dealing with possible cofounders. Conclusion: The limitations of this study suggest a need for more well-designed studies with a longer duration of follow-up on this topic to reach more reliable evidence.

show abstract

Section: Discussionmentioning

confidence: 94%